14B · Registry Watch
Registry Watch
Bookmarks need a Mind Club sign-in. How sign-in works
All 70 watchlist trials were pulled today, and none changed since 11.19 in status, enrollment, primary outcome or dates. Three have posted results. The full list, by primary completion date, runs on Fridays.
| Trial | Phase | Status | N | Primary completion |
|---|---|---|---|---|
| ANTHEM-UC (icotrokinra UC) Ph2b · NCT06049017 (opens another website in a new tab) | Phase 2 | Completed | 252 | 09.26.2024 |
| Explore-CKD · NCT06150924 (opens another website in a new tab) | Phase 2 | Completed | 60 | 02.27.2025 |
| TransportNPC · NCT04860960 (opens another website in a new tab) | Phase 3 | Unknown | 94 | 06.2025 |
| SatraGO-1 (satralizumab TED) · NCT05987423 (opens another website in a new tab) | Phase 3 | Completed | 131 | 07.08.2025 |
| SatraGO-2 (satralizumab TED) · NCT06106828 (opens another website in a new tab) | Phase 3 | Completed | 127 | 07.24.2025 |
| ZUPREME-1 · NCT06662539 (opens another website in a new tab) | Phase 2 | Completed | 493 | 09.30.2025 |
| B-Well 2 · NCT05630820 (opens another website in a new tab) | Phase 3 | Completed | 857 | 11.03.2025 |
| B-Well 1 · NCT05630807 (opens another website in a new tab) | Phase 3 | Completed | 981 | 11.11.2025 |
| RINGSIDE · NCT04871282 (opens another website in a new tab) | Phase 2/3 | Active, not recruiting | 198 | 12.03.2025 |
| SYNCHRONIZE-2 · NCT06066528 (opens another website in a new tab) | Phase 3 | Completed | 755 | 12.12.2025 |
| Olatorepatide (HS-20094) LIGHTEN Ph3 · NCT06839664 (opens another website in a new tab) | Phase 3 | Completed | 604 | 01.04.2026 |
| TALAPRO-3 · NCT04821622 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 599 | 02.18.2026 |
| ACHIEVE-4 · NCT05803421 (opens another website in a new tab) | Phase 3 | Completed | 2,749 | 03.16.2026 |
| Tulisokibart HS Ph2b · NCT06956235 (opens another website in a new tab) | Phase 2 | Active, not recruiting | 149 | 04.02.2026 |
| OVX836 Ph2b (Osivax) · NCT05569239 (opens another website in a new tab) | Phase 2 | Completed | 2,891 | 05.18.2026 |
| Krascendo 1 (divarasib NSCLC) Ph3 · NCT06497556 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 338 | 05.19.2026 |
| CLARITY-Gastric01 Ph3 · NCT06346392 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 594 | 05.31.2026 |
| Afimetoran SLE Ph2 · NCT04895696 (opens another website in a new tab) | Phase 2 | Active, not recruiting | 248 | 06.12.2026 |
| TRIUMPH-2 · NCT05929079 (opens another website in a new tab) | Phase 3 | Completed | 1,152 | 06.16.2026 |
| COURAGE (trevogrumab) Ph2 · NCT06299098 (opens another website in a new tab) | Phase 2 | Completed | 1,005 | 06.16.2026 |
| ARTEMIS-011 · NCT06935409 (opens another website in a new tab) | Phase 3 | Completed | 122 | 06.17.2026 |
| MRT-8102 Ph1 · NCT07119125 (opens another website in a new tab) | Phase 1 | Active, not recruiting | 100 | 07.2026 |
| EloraTZP Ph2 · NCT06603571 (opens another website in a new tab) | Phase 2 | Completed | 367 | 07.01.2026 |
| SAFFRON (savolitinib) Ph3 · NCT05261399 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 341 | 07.06.2026 |
| CROSSING (tezepelumab, EoE) Ph3 · NCT05583227 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 368 | 07.14.2026 |
| Seabreeze STAT · NCT06940154 (opens another website in a new tab) | Phase 2 | Completed | 159 | 07.30.2026 |
| ARISE (solengepras, Parkinson’s) Ph3 · NCT06553027 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 330 | 08.2026 |
| ZP9830 Phase 1 · NCT06682975 (opens another website in a new tab) | Phase 1 | Recruiting | 124 | 08.2026 |
| Tulisokibart UC Ph3 · NCT06052059 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 1,109 | 08.12.2026 |
| BMF-650 Ph1 · NCT07223216 (opens another website in a new tab) | Phase 1 | Completed | 90 | 08.12.2026 |
| DYNASTY-Breast02 Ph3 · NCT06018337 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 541 | 08.12.2026 |
| WHISTLE-PF (taladegib IPF) · NCT06422884 (opens another website in a new tab) | Phase 2 | Completed | 213 | 08.21.2026 |
| MAXPIRe (axatilimab IPF) Ph2 · NCT06132256 (opens another website in a new tab) | Phase 2 | Completed | 145 | 08.27.2026 |
| TRANSCEND-T2D-2 · NCT06260722 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 1,250 | 08.27.2026 |
| HERMES (ziltivekimab HFpEF) Ph3 · NCT05636176 (opens another website in a new tab) | Phase 3 | Terminated | 4,874 | 09.03.2026 |
| APOLLO, bitopertin EPP · NCT06910358 (opens another website in a new tab) | Phase 3 | Completed | 183 | 09.08.2026 |
| CLARITY (brepocitinib, uveitis) Ph3 · NCT06431373 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 371 | 09.11.2026 |
| OPUS-1 (VAX-31 adults) · NCT07284654 (opens another website in a new tab) | Phase 3 | Completed | 4,049 | 09.17.2026 |
| HARMONi-GI1 Ph3 · NCT06591520 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 682 | 10.2026 |
| FURVENT (firmonertinib 1L EGFR ex20 NSCLC) · NCT05607550 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 398 | 10.06.2026 |
| ALOFT-IPF (admilparant) · NCT06003426 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 1,255 | 10.06.2026 |
| LIBREXIA-STROKE (milvexian) Ph3 · NCT05702034 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 12,523 | 10.15.2026 |
| EVERLAST-B · NCT07290569 (opens another website in a new tab) | Phase 2 | Active, not recruiting | 160 | 10.21.2026 |
| ALTITUDE-AD (Acumen sabirnetug) · NCT06335173 (opens another website in a new tab) | Phase 2 | Active, not recruiting | 542 | 10.29.2026 |
| APEX (APG777) Ph2 · NCT06395948 (opens another website in a new tab) | Phase 2 | Active, not recruiting | 470 | 11.2026 |
| Tilrekimig AD Ph2 · NCT05995964 (opens another website in a new tab) | Phase 2 | Active, not recruiting | 507 | 11.12.2026 |
| ACTION-1 (RYZ101) · NCT05477576 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 343 | 12.2026 |
| VQW-765 Study 3201 Ph3 · NCT07221578 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 500 | 12.2026 |
| FB102-301 (celiac) Ph2 · NCT06982963 (opens another website in a new tab) | Phase 2 | Recruiting | 100 | 02.28.2027 |
| Ubamatamab Ph1/2 · NCT03564340 (opens another website in a new tab) | Phase 1/2 | Recruiting | 890 | 05.10.2027 |
| KEYNOTE-C93 · NCT05173987 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 280 | 05.27.2027 |
| EPCORE DLBCL-2 (epcoritamab + R-CHOP) · NCT05578976 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 900 | 06.2027 |
| ARO-MAPT Ph1/2a · NCT07221344 (opens another website in a new tab) | Phase 1/2 | Recruiting | 160 | 06.2027 |
| TUPELO (REC-4881, FAP) · NCT05552755 (opens another website in a new tab) | Phase 1/2 | Recruiting | 67 | 06.2027 |
| UNITY (efgartigimod SC, Sjogren’s) Ph3 · NCT06684847 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 631 | 07.2027 |
| FORTIFY (BBP-418) · NCT05775848 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 112 | 09.2027 |
| Combi-TED, Tedopi · NCT04884282 (opens another website in a new tab) | Phase 2 | Active, not recruiting | 105 | 09.30.2027 |
| EXCALIBER-RRMM (iberdomide) · NCT04975997 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 939 | 11.16.2027 |
| C-POST Ph3 · NCT03969004 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 415 | 01.07.2028 |
| TroFuse-005 · NCT06132958 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 710 | 01.10.2028 |
| IMAgINATION (sefaxersen IgAN) Ph3 · NCT05797610 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 459 | 05.25.2028 |
| SANOVO Ph3 · NCT05009836 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 412 | 05.30.2028 |
| Duvakitug HS Ph2b · NCT07812116 (opens another website in a new tab) | Phase 2 | Recruiting | 156 | 06.16.2028 |
| Vortosiran AF Ph2b (Ribocure) · NCT07870889 (opens another website in a new tab) | Phase 2 | Not yet recruiting | 150 | 07.31.2028 |
| VS-7375 TARGET-D 101 · NCT07020221 (opens another website in a new tab) | Phase 1/2 | Recruiting | 616 | 12.2028 |
| AHEAD-MERIT (BNT113) · NCT04534205 (opens another website in a new tab) | Phase 2/3 | Active, not recruiting | 358 | 04.2029 |
| MOIO · NCT05078047 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 646 | 05.07.2029 |
| AMT-130 Ph1/2 · NCT04120493 (opens another website in a new tab) | Phase 1/2 | Active, not recruiting | 43 | 06.2029 |
| TARGET-CD, ABBV-466 · NCT06548542 (opens another website in a new tab) | Phase 2 | Recruiting | 590 | 01.2030 |
| DeLLphi-305 (tarlatamab + durvalumab ES-SCLC) Ph3 · NCT06211036 (opens another website in a new tab) | Phase 3 | Active, not recruiting | 563 | 04.02.2030 |
ClinicalTrials.gov watchlist, pulled 11.20.2026 through the registry’s API Reg. N is actual or planned enrollment as registered. A listed completion date is the sponsor’s estimate and can move.